Nachweis spezifischer T-Zell-vermittelter Immunantworten gegen Tumor assoziierte Antigene bei Lungenkrebs
Steinhauser, Maximilian Felix
Recently, new approaches like kinase inhibitors and monoclonal antibodies and immunotherapy showed promising results in lung cancer therapy. Vaccination with TAAs, such as MAGE-A3 and hTERT are beeing tested in phase III studies. Therefore it is important to identify new immunogenic targets for immunotherapy. In this study, t-cell mediated specific immune response against 11 peptide epitopes have been tested in patients with advanced NSCLC (n=12) and SCLC (n=2), who haven been selected for HLA-A2 expression from 35 Patients. Therefore mixed lymphocyte/peptide culture and ELISpot assays for interferon gamma and granzyme B were performed. Peptides derived from TAAs RHAMM, PRAME, WT-1, hTERT, Survivin, MAGE A3, G250, HER2 and aurora kinases A and B were tested. 13 of 14 patients showed cellular immune response against at least 1 peptide. Every peptide was able to induce positive reactions in at least 3 patients in one ELISpot assay. G250 G2 and PRAME P3 seem to be interesting targets for immunotherapies, as they induced t-cellular mediated immune response 67 % and 64 % of patients. Both TAAs are expressed by lung cancer in high frequency. This work showed, that patients with advanced lung cancer are able to generate specific t-cell mediated immune responses against varoius peptides epitopes derived from tumor associated antigens. Therefore these peptides are potential targets for immunotherapies against lung cancer.
Subject HeadingsBronchialkrebs [GND]
Bronchial neoplasms [MeSH]